108868-60-6

Basic information

• Product Name: (3S,4S)-1-<<(3-methylbutyl)carbonyl>amino>-3-hydroxy-4-<(tert-butyloxycarbonyl)amino>-5-cyclohexylpentane
• Synonyms: (3S,4S)-1-<<(3-methylbutyl)carbonyl>amino>-3-hydroxy-4-<(tert-butyloxycarbonyl)amino>-5-cyclohexylpentane
• CAS NO: 108868-60-6
• Molecular Weight: 398.586
• Mol File: 108868-60-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (3S,4S)-1-<<(3-methylbutyl)carbonyl>amino>-3-hydroxy-4-<(tert-butyloxycarbonyl)amino>-5-cyclohexylpentane(CAS DataBase Reference)
• NIST Chemistry Reference: (3S,4S)-1-<<(3-methylbutyl)carbonyl>amino>-3-hydroxy-4-<(tert-butyloxycarbonyl)amino>-5-cyclohexylpentane(108868-60-6)
• EPA Substance Registry System: (3S,4S)-1-<<(3-methylbutyl)carbonyl>amino>-3-hydroxy-4-<(tert-butyloxycarbonyl)amino>-5-cyclohexylpentane(108868-60-6)

Safety Data

• Hazardous Substances Data: 108868-60-6(Hazardous Substances Data)

Upstream product

• 38136-29-7 4-methylvaleroyl chloride 
• 108868-55-9 (3S,4S)-1-amino-3-hydroxy-4-<(tert-butyloxycarbonyl)amino>-5-cyclohexylpentane 
• 98105-42-1 (S)-2-(t-butoxycarbonylamino)-3-cyclohexyl-1-propanal 
• 107202-61-9 (2R,3S)-3-(t-butoxycarbonylamino)-4-cyclohexyl-1,2-epoxybutane 
• 108868-54-8 (3S,4S)-3-hydroxy-4-<(tert-butyloxycarbonyl)amino>-5-cyclohexylpentanenitrile 

Downstream Products

• 108868-76-4 [(S)-1-[(S)-1-[(1S,2S)-1-Cyclohexylmethyl-2-hydroxy-4-(4-methyl-pentanoylamino)-butylcarbamoyl]-2-(1H-imidazol-4-yl)-ethylcarbamoyl]-2-(4-methoxy-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 108868-72-0 {(S)-1-[(S)-1-[(1S,2S)-1-Cyclohexylmethyl-2-hydroxy-4-(4-methyl-pentanoylamino)-butylcarbamoyl]-2-(3-methyl-3H-imidazol-4-yl)-ethylcarbamoyl]-2-phenyl-ethyl}-carbamic acid tert-butyl ester 
• 108868-75-3 ((S)-1-{1-[(1S,2S)-1-Cyclohexylmethyl-2-hydroxy-4-(4-methyl-pentanoylamino)-butylcarbamoyl]-2-pyrimidin-4-yl-ethylcarbamoyl}-2-phenyl-ethyl)-carbamic acid tert-butyl ester 
• 108868-74-2 {(S)-1-[1-[(1S,2S)-1-Cyclohexylmethyl-2-hydroxy-4-(4-methyl-pentanoylamino)-butylcarbamoyl]-2-(1H-pyrazol-3-yl)-ethylcarbamoyl]-2-phenyl-ethyl}-carbamic acid tert-butyl ester 
• 108868-70-8 {(S)-1-[(S)-1-[(1S,2S)-1-Cyclohexylmethyl-2-hydroxy-4-(4-methyl-pentanoylamino)-butylcarbamoyl]-2-(1H-imidazol-4-yl)-ethylcarbamoyl]-2-phenyl-ethyl}-carbamic acid tert-butyl ester 
• 108868-73-1 ((S)-1-{1-[(1S,2S)-1-Cyclohexylmethyl-2-hydroxy-4-(4-methyl-pentanoylamino)-butylcarbamoyl]-2-thiazol-4-yl-ethylcarbamoyl}-2-phenyl-ethyl)-carbamic acid tert-butyl ester 
• 108868-71-9 {(S)-1-[(S)-1-[(1S,2S)-1-Cyclohexylmethyl-2-hydroxy-4-(4-methyl-pentanoylamino)-butylcarbamoyl]-2-(1-methyl-1H-imidazol-4-yl)-ethylcarbamoyl]-2-phenyl-ethyl}-carbamic acid tert-butyl ester 
• 108868-69-5 ((S)-1-{(S)-1-[(1S,2S)-1-Cyclohexylmethyl-2-hydroxy-4-(4-methyl-pentanoylamino)-butylcarbamoyl]-2-phenyl-ethylcarbamoyl}-2-phenyl-ethyl)-carbamic acid tert-butyl ester 
• 108868-68-4 ((S)-1-{(S)-1-[(1S,2S)-1-Cyclohexylmethyl-2-hydroxy-4-(4-methyl-pentanoylamino)-butylcarbamoyl]-ethylcarbamoyl}-2-phenyl-ethyl)-carbamic acid tert-butyl ester 
• 108868-80-0 Boc-(?-N-methyl)His amide of (3S,4S)-1-<<(3-methylbutyl)carbonyl>amino>-3-hydroxy-4-amino-5-cyclohexylpentane 
• 108868-82-2 Boc-dl-(4-pyrimidinyl)Ala amide of (3S,4S)-1-<<(3-methylbutyl)carbonyl>amino>-3-hydroxy-4-amino-5-cyclohexylpentane 
• 108868-81-1 Boc-(τ-N-methyl)His amide of (3S,4S)-1-<<(3-methylbutyl)carbonyl>amino>-3-hydroxy-4-amino-5-cyclohexylpentane 
• 108868-85-5 Boc-His amide of (3S,4S)-1-<<(3-methylbutyl)carbonyl>amino>-3-hydroxy-4-amino-5-cyclohexylpentane 

Relevant articles and documents

Angiotensinogen analogs

The invention relates to renin inhibiting compounds of the formula STR1 wherein A is hydrogen; loweralkyl; arylalkyl; OR10 or SR10 wherein R10 is hydrogen, loweralkyl or aminoalkyl; NR11 R12 wherein R11 and R12 are independently selected from hydrogen, loweralkyl, aminoalkyl, cyanoalkyl and hydroxyalkyl; STR2 wherein B is NH, alkylamino, S, O, CH2 or CHOH and R13 is loweralkyl, cycloalkyl, aryl, arylalkyl, alkoxy, alkenyloxy, hydroxyalkoxy, dihydroxyalkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, (hydroxyalkyl)(alkyl)amino, (dihydroxyalkyl)(alkyl)amino, aminoalkyl, alkoxycarbonylalkyl, carboxyalkyl, N-protected aminoalkyl, alkylaminoalkyl, (N-protected)(alkyl)aminoalkyl, dialkylaminoalkyl, (heterocyclic) alkyl or a substituted or unsubstituted heterocyclic; W is CO or CHOH and U is CH2 or NR2 with the proviso that when W is CHOH then U is CH2 ; R1 is loweralkyl, cycloaklylmethyl, benzyl, α,α-dimethylbenzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, (4-imidazoyl)-methyl, phenethyl, phenoxy, thiophenoxy or anilino; provided if R1 is phenoxy, thiophenoxy or anilino, B is CH2 or CHOH or A is hydrogen, R3 is loweralkyl, vinylloweralkyl, benzyl or heterocyclic ring substituted methyl, R5 is loweralkyl, cycloalkylmethyl or benzyl; R2 and R4 are independently selected from hydrogen and loweralkyl; R6 is CHOH or CO; R7 is CH2, CF2 or CF with the proviso that when R6 is CO, R7 is CF2 ; R8 is CH2, CHR14 wherein R14 is lower-alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, or R7 and R8 taken together can be STR3 with the proviso that when R7 is CF2, R8 is CH2 ; E is O, S, SO, SO2, NR15 wherein R15 is hydrogen or loweralkyl or NR16 CO wherein R16 is hydrogen or loweralkyl; R9 is loweralkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or an N-protected group, or E and R9 taken together can be N3, with the proviso that when E is NH, R9 is an N-protecting group; and pharmaceutically acceptable salts thereof.